Umjovo wehepatitis A

Umjovo wehepatitis A ngumjovo lovikela ihepatitis A.^[1] Usebente kahle kakhulu kubantfu labagulako labangu 95% kantsi ube khona lokungenani iminyaka lelishumi nesihlanu nesikhatsi umuntfu langahle asiphile.^[1]^[2] Uma uniketwa, emadosi lamabili ayaconywa ekucaleni ngemuva kwemnyaka munye. Uniketwa ngekukujova emsipheni.^[1]

Inhlangano Yetemphilo Mhlabawonkhe (i-WHO) incoma imijova lesebenta ndzawotonkhe etindzaweni lapho ungakavami kangako. Lapho lesifo sijwayeleke khona imijovo lesabalele ayinconywa njengoba bonkhe bantfu bavame kungenwa kusuleleka ngetifo ngemntfwana.^[1] Sikhungo Lesilawula Nalesivikela Tifo (i-CDC) incoma kujovwa kwebantfu labadzala labasengotini kakhulu nabo bonkhe bantfwana.^[3]

Imitselela lemibi lecacile ayikavamisi kwenteka. Kuba khona tinhlungu kulelicala lelijoviwe lobulinganiselwa ku-15% kubantfwana nehhafu yebantfu labadzala. Imijovo leminyenti yehepatitis A icuketse emagciwane langaphili ngalesikhatsi leminye inemagciwane langenamandla. Lena lenemagciwane lengenamandla akufanele itsatfwe ngalesikhatsi ukhulelwe noma kulabo labanemasotja langasebenti kahle. Kwakheka lokumbalwa kwenhlanganisela yehepatitis A mhlawumbe nehepatitis B noma umjovo wethayifodi.^[1]

Umjovo wekucala we-A wavunyelwa e-Europe nga-1991 nase United States nga-1995.^[4] KukuLuhla Lwemitsi Lebalulekile Lwenhlangano Yetemphilo Mhlabawonkhe, umutsi lobaluleke kakhulu lodzingekako kuloluhlelo lolusisekelo lwetemphilo.^[5] E-United States ubita emkhatsini wa-50 na 100 USD.^[6] iThempleti:Drugbox

Emareferensi

↑ ^1.0 ^1.1 ^1.2 ^1.3 ^1.4 "WHO position paper on hepatitis A vaccines – June 2012" (PDF). Wkly Epidemiol Rec. 87 (28/29): 261-76. 2012 Jul 13. PMID 22905367.
↑ Ott JJ, Irving G, Wiersma ST (December 2012). "Long-term protective effects of hepatitis A vaccines. A systematic review". Vaccine. 31 (1): 3–11. doi:10.1016/j.vaccine.2012.04.104. PMID 22609026.
↑ "Hepatitis A In-Short". CDC. July 25, 2014. Retrieved 7 December 2015.
↑ Patravale, Vandana; Dandekar, Prajakta; Jain, Ratnesh (2012). Nanoparticulate drug delivery perspectives on the transition from laboratory to market (1. publ. ed.). Oxford: Woodhead Pub. p. 212. ISBN 9781908818195.
↑ "19th WHO Model List of Essential Medicines (April 2015)" (PDF). WHO. April 2015. Retrieved May 10, 2015.
↑ Hamilton, Richart (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 314. ISBN 9781284057560.

[:0-1] 1.0 ^1.1 ^1.2 ^1.3 ^1.4 "WHO position paper on hepatitis A vaccines – June 2012" (PDF). Wkly Epidemiol Rec. 87 (28/29): 261-76. 2012 Jul 13. PMID 22905367.

[2] Ott JJ, Irving G, Wiersma ST (December 2012). "Long-term protective effects of hepatitis A vaccines. A systematic review". Vaccine. 31 (1): 3–11. doi:10.1016/j.vaccine.2012.04.104. PMID 22609026.

[3] "Hepatitis A In-Short". CDC. July 25, 2014. Retrieved 7 December 2015.

[4] Patravale, Vandana; Dandekar, Prajakta; Jain, Ratnesh (2012). Nanoparticulate drug delivery perspectives on the transition from laboratory to market (1. publ. ed.). Oxford: Woodhead Pub. p. 212. ISBN 9781908818195.

[5] "19th WHO Model List of Essential Medicines (April 2015)" (PDF). WHO. April 2015. Retrieved May 10, 2015.

[6] Hamilton, Richart (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 314. ISBN 9781284057560.

[1]

[2]

[3]

[4]

[5]

[6]